JP2017525354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017525354A5 JP2017525354A5 JP2017505807A JP2017505807A JP2017525354A5 JP 2017525354 A5 JP2017525354 A5 JP 2017525354A5 JP 2017505807 A JP2017505807 A JP 2017505807A JP 2017505807 A JP2017505807 A JP 2017505807A JP 2017525354 A5 JP2017525354 A5 JP 2017525354A5
- Authority
- JP
- Japan
- Prior art keywords
- cell death
- high affinity
- programmed cell
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 63
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 63
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- 102220496972 Platelet-activating factor acetylhydrolase 2, cytoplasmic_K53T_mutation Human genes 0.000 claims 18
- 102220058921 rs786202731 Human genes 0.000 claims 18
- 102200118229 rs34665886 Human genes 0.000 claims 17
- 102220161672 rs148219510 Human genes 0.000 claims 13
- 102220586093 Homeobox protein DLX-1_V39R_mutation Human genes 0.000 claims 10
- 102220354149 c.289C>A Human genes 0.000 claims 10
- 102220568823 Dual specificity mitogen-activated protein kinase kinase 1_G65V_mutation Human genes 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 102220249043 rs145159429 Human genes 0.000 claims 9
- 102220226094 rs17217723 Human genes 0.000 claims 9
- 102220311149 rs41271047 Human genes 0.000 claims 9
- 102220279022 rs955258267 Human genes 0.000 claims 9
- 102220507725 GTP-binding protein RAD_Q66P_mutation Human genes 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 7
- 102220585589 Short-chain dehydrogenase/reductase family 42E member 1_Q63P_mutation Human genes 0.000 claims 7
- 102220361097 c.307C>T Human genes 0.000 claims 5
- 230000003278 mimic effect Effects 0.000 claims 5
- 102220013742 rs397516741 Human genes 0.000 claims 5
- 102220257864 rs1050971384 Human genes 0.000 claims 4
- 102220198136 rs1057519882 Human genes 0.000 claims 4
- 102200116701 rs115206969 Human genes 0.000 claims 4
- 102220250913 rs1364636517 Human genes 0.000 claims 4
- 102220624338 Interferon alpha-8_T51A_mutation Human genes 0.000 claims 3
- 102220492589 Protein numb homolog_S48D_mutation Human genes 0.000 claims 3
- 102220477170 Y-box-binding protein 2_S102A_mutation Human genes 0.000 claims 3
- 102220364119 c.148C>A Human genes 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 102200007406 rs148775298 Human genes 0.000 claims 3
- 102200017902 rs267606847 Human genes 0.000 claims 3
- 102220252689 rs373178770 Human genes 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102220492635 Integrin alpha-3_D52Y_mutation Human genes 0.000 claims 2
- 102100040418 Tumor protein D52 Human genes 0.000 claims 2
- 102220555263 Tumor protein D52_D52Y_mutation Human genes 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102220487428 Actin-related protein 2/3 complex subunit 3_R90K_mutation Human genes 0.000 claims 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 229940123189 CD40 agonist Drugs 0.000 claims 1
- 108010062802 CD66 antigens Proteins 0.000 claims 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 102220349284 c.287A>T Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 102200160087 rs1131692231 Human genes 0.000 claims 1
- 102220126393 rs886044243 Human genes 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462035316P | 2014-08-08 | 2014-08-08 | |
| US62/035,316 | 2014-08-08 | ||
| US201562150789P | 2015-04-21 | 2015-04-21 | |
| US62/150,789 | 2015-04-21 | ||
| PCT/US2015/044356 WO2016022994A2 (en) | 2014-08-08 | 2015-08-07 | High affinity pd-1 agents and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017525354A JP2017525354A (ja) | 2017-09-07 |
| JP2017525354A5 true JP2017525354A5 (enExample) | 2018-09-13 |
| JP6945444B2 JP6945444B2 (ja) | 2021-10-06 |
Family
ID=55264785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505807A Active JP6945444B2 (ja) | 2014-08-08 | 2015-08-07 | 高親和性ｐｄ−１薬剤とその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10800830B2 (enExample) |
| EP (2) | EP3699189A1 (enExample) |
| JP (1) | JP6945444B2 (enExample) |
| CN (1) | CN107108707A (enExample) |
| CA (1) | CA2994927A1 (enExample) |
| CY (1) | CY1123385T1 (enExample) |
| DK (1) | DK3177640T3 (enExample) |
| ES (1) | ES2819451T3 (enExample) |
| HR (1) | HRP20201153T1 (enExample) |
| HU (1) | HUE050406T2 (enExample) |
| PL (1) | PL3177640T3 (enExample) |
| PT (1) | PT3177640T (enExample) |
| WO (1) | WO2016022994A2 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| JP6945444B2 (ja) * | 2014-08-08 | 2021-10-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｐｄ−１薬剤とその使用方法 |
| CA2961987A1 (en) * | 2014-09-30 | 2016-04-07 | Intervet International B.V. | Pd-l1 antibodies binding canine pd-l1 |
| MX385081B (es) | 2014-11-25 | 2025-03-14 | Bristol Myers Squibb Co | Métodos y composiciones para radioetiquetado con 18f de productos biológicos. |
| EP3702367B1 (en) | 2014-11-25 | 2024-05-15 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
| EP3089761B1 (en) | 2015-03-02 | 2019-06-12 | Innovative Cellular Therapeutics Co., Ltd. | Reducing immune tolerance induced by pd l1 |
| MX2017012966A (es) * | 2015-04-10 | 2018-06-06 | Amgen Inc | Muteinas de interleuquina 2 para la expansion de celulas t regulatorias. |
| PT3283508T (pt) | 2015-04-17 | 2021-06-21 | Alpine Immune Sciences Inc | Proteínas imuno modulatórias com afinidades afináveis |
| PT3298033T (pt) | 2015-05-18 | 2020-09-22 | Tcr2 Therapeutics Inc | Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| BR112018000917A2 (pt) | 2015-07-16 | 2018-09-11 | Bioxcel Therapeutics Inc | abordagem inovadora para o tratamento de câncer através da imunomodulação |
| IL256989B (en) | 2015-08-07 | 2022-08-01 | Alx Oncology Inc | Constructs with a sirp-alpha site or a variant thereof |
| US11219694B2 (en) | 2015-09-24 | 2022-01-11 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| KR102824067B1 (ko) | 2016-04-15 | 2025-06-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| MA43552A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
| US11352413B2 (en) * | 2016-05-17 | 2022-06-07 | Albert Einstein College Of Medicine | Engineered PD-1 variants |
| WO2017210302A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Pet imaging with pd-l1 binding polypeptides |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| RU2656181C1 (ru) * | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3033105A1 (en) | 2016-08-11 | 2018-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
| WO2018067361A1 (en) * | 2016-10-04 | 2018-04-12 | The Curators Of The University Of Missouri | Peptides for molecular detection of pd-l1 |
| CA3036745A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| CN110392694B (zh) | 2016-11-02 | 2023-08-04 | 震动疗法股份有限公司 | 针对pd-1的抗体及其用途 |
| CA3043373A1 (en) | 2016-11-09 | 2018-05-17 | Healthtell Inc. | Pre-assembled, protected, chemically stable, chemoselective linkers |
| CN110036058A (zh) | 2016-11-09 | 2019-07-19 | 健康之语公司 | 具有可调节胺密度的涂层 |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharmaceuticals, Inc. | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
| LT3565579T (lt) * | 2017-01-05 | 2023-09-11 | Kahr Medical Ltd. | Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| JP7167041B2 (ja) | 2017-02-10 | 2022-11-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| US11732022B2 (en) | 2017-03-16 | 2023-08-22 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| JP7346302B2 (ja) * | 2017-03-28 | 2023-09-19 | オハイオ・ステイト・イノベーション・ファウンデーション | ヒトｐｄ－１ペプチドワクチン及びその使用法 |
| WO2018192443A1 (zh) * | 2017-04-17 | 2018-10-25 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种多肽及其应用 |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CA3064869A1 (en) * | 2017-05-26 | 2018-11-29 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| CN110997013B (zh) | 2017-07-24 | 2022-09-20 | 瑞泽恩制药公司 | 抗cd8抗体和其用途 |
| US20200206344A1 (en) * | 2017-08-21 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Methods for modulating the interaction between ews-fli1 and baf complexes |
| CN111801347A (zh) | 2017-10-10 | 2020-10-20 | 高山免疫科学股份有限公司 | Ctla-4变体免疫调节蛋白和其用途 |
| AU2018351006B2 (en) | 2017-10-18 | 2024-08-29 | Forty Seven, LLC | Anti-CD47 agent-based ovarian cancer therapy |
| WO2019079520A2 (en) | 2017-10-18 | 2019-04-25 | Alpine Immune Sciences, Inc. | ICOS VARIANT LIGAND IMMUNOMODULATORY IMMUNOMODULATORY PROTEINS, COMPOSITIONS AND METHODS THEREOF |
| CN107916255B (zh) * | 2017-11-16 | 2021-06-04 | 复旦大学 | Pdl-1基因靶向特异性甲基化表观遗传修饰抗肿瘤分子及其用途 |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CA3089319A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| JP2021512166A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 化合物及びその使用 |
| BR112020015884A2 (pt) | 2018-02-06 | 2020-12-08 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| US12240870B2 (en) | 2018-02-23 | 2025-03-04 | Purdue Research Foundation | Sequencing method for CAR T cell therapy |
| CN108794619B (zh) * | 2018-05-31 | 2021-09-17 | 郑州大学 | 一种高亲和pd-1蛋白突变体 |
| JP2021525806A (ja) | 2018-06-01 | 2021-09-27 | タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド | 疾患または状態を処置するための組成物およびそれらの使用 |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| US12134638B2 (en) | 2018-07-11 | 2024-11-05 | Kahr Medical Ltd. | SIRPalpha-4-1BBL variant fusion protein and methods of use thereof |
| KR20210044221A (ko) * | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법 |
| CN108997492B (zh) * | 2018-07-19 | 2022-04-12 | 海珂分子（北京）科技有限责任公司 | 高亲和力的pd1胞外区突变体多肽及相关融合蛋白 |
| AU2019338416A1 (en) * | 2018-09-14 | 2021-04-29 | Akso Biopharmaceutical, Inc. | sPD-1 variant - Fc fusion proteins |
| US12390541B2 (en) * | 2018-09-26 | 2025-08-19 | Albert Einstein College Of Medicine | Mutant variants of PD-1 receptor with selective binding to PD-L1 and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020102365A1 (en) * | 2018-11-14 | 2020-05-22 | Healthtell Inc. | Methods of selecting functional interface mimics, and compositions thereof |
| CA3120715A1 (en) | 2018-11-21 | 2020-05-28 | Mayo Foundation For Medical Education And Research | Adenoviruses and methods for using adenoviruses |
| CN111100199B (zh) * | 2018-12-29 | 2021-02-12 | 北京百普赛斯生物科技股份有限公司 | 一种荧光素标记的蛋白四聚体及其制备方法与应用 |
| EP3914623A4 (en) | 2019-01-23 | 2022-11-23 | Tayu Huaxia Biotech Medical Group Co., Ltd. | ANTI-PD-L1 DIABODIES AND THEIR USE |
| EP3917529A4 (en) | 2019-01-29 | 2022-11-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN111714618B (zh) * | 2019-03-22 | 2024-07-12 | 香雪生命科学技术（广东）有限公司 | T细胞和高亲和力pd-1融合蛋白的组合 |
| CN110054701B (zh) * | 2019-04-17 | 2022-12-27 | 中国医学科学院血液病医院（血液学研究所） | 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用 |
| MX2021010577A (es) | 2019-04-29 | 2021-10-13 | Mayo Found Medical Education & Res | Compuestos de union a pd-l1 multivalentes para tratar cancer. |
| BR112021021200A2 (pt) | 2019-05-01 | 2021-12-21 | Juno Therapeutics Inc | Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos |
| WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| KR20220044904A (ko) | 2019-05-31 | 2022-04-12 | 알렉소 온콜로지 인크. | 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법 |
| CN112279923B (zh) * | 2019-07-22 | 2023-07-18 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体及其应用 |
| CA3157416A1 (en) * | 2019-11-14 | 2021-05-20 | George Coukos | Compositions and methods for immunotherapy |
| JP7650047B2 (ja) * | 2019-11-27 | 2025-03-24 | 株式会社 MiyaCare Therapeutics | 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１ |
| CN115023226A (zh) | 2020-01-29 | 2022-09-06 | 福宏治疗公司 | 化合物及其用途 |
| KR102623161B1 (ko) * | 2020-10-08 | 2024-01-09 | 고려대학교 산학협력단 | Pd-l1 친화도가 증가된 pd-1 변이체 |
| US12473349B2 (en) | 2020-05-06 | 2025-11-18 | Korea University Research And Business Foundation | PD-1 variants having increased PD-L1 affinity |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| CN115884988A (zh) * | 2020-05-28 | 2023-03-31 | 小利兰·斯坦福大学托管委员会 | 防止封闭和半封闭空间中病毒和微生物污染的雾化粘液抑制纳米抗体 |
| CN116234558A (zh) | 2020-06-26 | 2023-06-06 | 朱诺治疗学有限公司 | 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法 |
| US20230414660A1 (en) * | 2020-11-13 | 2023-12-28 | Ludwig Institute For Cancer Research Ltd | Pd-1 decoy variants for immunotherapy |
| CN112999368A (zh) * | 2021-04-09 | 2021-06-22 | 广东药康生物科技有限公司 | 人源化模型进行药效评价方法的建立 |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| EP4436615A1 (en) * | 2021-11-26 | 2024-10-02 | Vita Therapeutics, Inc. | Immune cell therapy of pd-l1 positive cancers |
| CN117777303A (zh) * | 2022-09-27 | 2024-03-29 | 北京大学 | 一种高亲和力pd1蛋白偶联物及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| WO1993003769A1 (en) | 1991-08-20 | 1993-03-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
| BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| EP1083231A1 (en) | 1999-09-09 | 2001-03-14 | Introgene B.V. | Smooth muscle cell promoter and uses thereof |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US7332567B2 (en) | 2001-08-28 | 2008-02-19 | Allergan, Inc. | Fret protease assays for clostridial toxins |
| US7169874B2 (en) | 2001-11-02 | 2007-01-30 | Bausch & Lomb Incorporated | High refractive index polymeric siloxysilane compositions |
| PL1907424T3 (pl) * | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| JP2012500652A (ja) * | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| EA201500417A1 (ru) * | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| HUE028582T2 (en) | 2008-11-28 | 2016-12-28 | Univ Emory | Method for determining the efficacy of PD-1 antagonists |
| US20110189743A1 (en) * | 2009-10-06 | 2011-08-04 | Bio Architecture Lab, Inc. | Microbial systems for producing commodity chemicals |
| EP2638061B1 (en) * | 2010-11-11 | 2015-04-22 | The University of Hong Kong | Soluble pd-1 variants, fusion constructs, and uses thereof |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| EP2699264B1 (en) * | 2011-04-20 | 2018-03-14 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CA2843595C (en) * | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| US8956619B2 (en) * | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| ES2816647T3 (es) | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| EP2807194A4 (en) | 2012-01-27 | 2015-12-02 | Gliknik Inc | FUSION PROTEINS WITH IGG2 HINGEOMS |
| WO2013176915A1 (en) | 2012-05-25 | 2013-11-28 | Roman Galetto | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| MX370148B (es) | 2012-10-02 | 2019-12-03 | Memorial Sloan Kettering Cancer Center | Composiciones y su uso para inmunoterapia. |
| AU2013362789B8 (en) | 2012-12-17 | 2018-08-02 | Pfizer Inc. | Treatment of CD47+ disease cells with SIRP Alpha-Fc fusions |
| US20150368316A1 (en) | 2013-02-07 | 2015-12-24 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| JP6945444B2 (ja) * | 2014-08-08 | 2021-10-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性ｐｄ−１薬剤とその使用方法 |
| US9845345B2 (en) * | 2015-05-18 | 2017-12-19 | Ab Initio Biotherapeutics, Inc. | SIRP polypeptide compositions and methods of use |
-
2015
- 2015-08-07 JP JP2017505807A patent/JP6945444B2/ja active Active
- 2015-08-07 ES ES15829652T patent/ES2819451T3/es active Active
- 2015-08-07 HR HRP20201153TT patent/HRP20201153T1/hr unknown
- 2015-08-07 DK DK15829652.5T patent/DK3177640T3/da active
- 2015-08-07 EP EP20166891.0A patent/EP3699189A1/en active Pending
- 2015-08-07 WO PCT/US2015/044356 patent/WO2016022994A2/en not_active Ceased
- 2015-08-07 HU HUE15829652A patent/HUE050406T2/hu unknown
- 2015-08-07 EP EP15829652.5A patent/EP3177640B1/en active Active
- 2015-08-07 CN CN201580054333.5A patent/CN107108707A/zh active Pending
- 2015-08-07 US US15/502,439 patent/US10800830B2/en active Active
- 2015-08-07 CA CA2994927A patent/CA2994927A1/en active Pending
- 2015-08-07 PL PL15829652T patent/PL3177640T3/pl unknown
- 2015-08-07 US US14/821,589 patent/US9546206B2/en active Active
- 2015-08-07 PT PT158296525T patent/PT3177640T/pt unknown
- 2015-11-03 US US14/931,725 patent/US9562087B2/en active Active
-
2020
- 2020-05-26 US US16/883,396 patent/US11814419B2/en active Active
- 2020-08-05 CY CY20201100728T patent/CY1123385T1/el unknown
-
2023
- 2023-10-06 US US18/482,223 patent/US20240174729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017525354A5 (enExample) | ||
| Xiang et al. | Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 | |
| Hansen et al. | Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail | |
| Muzioł et al. | Structural basis for budding by the ESCRT-III factor CHMP3 | |
| Chen et al. | A DDX6-CNOT1 complex and W-binding pockets in CNOT9 reveal direct links between miRNA target recognition and silencing | |
| Ketema et al. | Requirements for the localization of nesprin-3 at the nuclear envelope and its interaction with plectin | |
| Di Giovine et al. | Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1 | |
| Liu et al. | A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection | |
| Dreyfus et al. | Highly conserved protective epitopes on influenza B viruses | |
| Li et al. | A molecular-level account of the antigenic hantaviral surface | |
| Peng et al. | Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody | |
| Morgan et al. | Syndecan-4 phosphorylation is a control point for integrin recycling | |
| Sillibourne et al. | Primary ciliogenesis requires the distal appendage component Cep123 | |
| Burgo et al. | A molecular network for the transport of the TI-VAMP/VAMP7 vesicles from cell center to periphery | |
| Friedrich et al. | DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety | |
| Sickmier et al. | The panitumumab EGFR complex reveals a binding mechanism that overcomes cetuximab induced resistance | |
| Pal et al. | Structural basis for phosphorylation-dependent recruitment of Tel2 to Hsp90 by Pih1 | |
| van Dinther et al. | Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling | |
| Håberg et al. | SNX18 is an SNX9 paralog that acts as a membrane tubulator in AP-1-positive endosomal trafficking | |
| Tousley et al. | Huntingtin associates with the actin cytoskeleton and α-actinin isoforms to influence stimulus dependent morphology changes | |
| van Roeyen et al. | Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities | |
| HRP20201153T1 (hr) | Pd-1 sredstva visokog afiniteta i načini uporabe | |
| JP2018519296A5 (enExample) | ||
| Hong et al. | Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants | |
| JP2017061471A5 (enExample) |